11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Timosan

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Timolol

Timolol

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Zetterberg M. Age-related eye disease and gender. Maturitas. 2016;83:19-26.

  2. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47(10):4254-61.

  3. Douglass A, Dattilo M, Feola AJ. Evidence for Menopause as a Sex-Specific Risk Factor for Glaucoma. Cell Mol Neurobiol. 2023;43(1):79-97.

  4. Ye X, She X, Shen L. Association of sex with the global burden of glaucoma: an analysis from the global burden of disease study 2017. Acta Ophthalmol. 2020;98(5):e593-e598.

  5. Xie JS, Kaur H, Tao B, Lee J, Solish D, Kohly R et al. Sex or Gender Reporting in Ophthalmology Clinical Trials Among US Food and Drug Administration Approvals, 1995 to 2022. JAMA Ophthalmol. 2024;142(2):123-130.

  6. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0005% latanoprost applied once daily, evening or morning A comparison with timolol Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743-52.

  7. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy Efficacy and safety after 1 year of treatment in 198 patients Latanoprost Study Groups. Ophthalmology. 1996;103:1916-24.

  8. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension The Latanoprost Study Group. Ophthalmology. 1996;103:126-37.

  9. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95-104.

  10. Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma. 2003;12:463-5.

  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Zetterberg M. Age-related eye disease and gender. Maturitas. 2016;83:19-26.
  2. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47(10):4254-61.
  3. Douglass A, Dattilo M, Feola AJ. Evidence for Menopause as a Sex-Specific Risk Factor for Glaucoma. Cell Mol Neurobiol. 2023;43(1):79-97.
  4. Ye X, She X, Shen L. Association of sex with the global burden of glaucoma: an analysis from the global burden of disease study 2017. Acta Ophthalmol. 2020;98(5):e593-e598.
  5. Xie JS, Kaur H, Tao B, Lee J, Solish D, Kohly R et al. Sex or Gender Reporting in Ophthalmology Clinical Trials Among US Food and Drug Administration Approvals, 1995 to 2022. JAMA Ophthalmol. 2024;142(2):123-130.
  6. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0005% latanoprost applied once daily, evening or morning A comparison with timolol Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743-52.
  7. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy Efficacy and safety after 1 year of treatment in 198 patients Latanoprost Study Groups. Ophthalmology. 1996;103:1916-24.
  8. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension The Latanoprost Study Group. Ophthalmology. 1996;103:126-37.
  9. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95-104.
  10. Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma. 2003;12:463-5.
  11. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]